Market cap
₹329 Cr
Recently Viewed
Clear AllNSE: NATHBIOGEN | BSE: 537291
₹172.00
₹-1.78
(-1.02%)
As on 28-Apr-2026IST
Market cap
₹329 Cr
Revenue (TTM)
₹445 Cr
P/E Ratio
7.6
P/B Ratio
0.5
Div. Yield
1.2 %
Today’s Range
52 Week Range
Liquidity
Net Profit (TTM)
₹43 Cr
ROE
6.2 %
ROCE
6.9 %
Industry P/E
15.87
EV/EBITDA
8.4
Debt to Equity
0.2
Book Value
₹358.6
EPS
₹20.4
Face value
10
Shares outstanding
19,004,000
CFO
₹77.98 Cr
EBITDA
₹445.14 Cr
Net Profit
₹250.29 Cr
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Nath Bio-Genes
| 10.6 | 32.0 | 23.7 | 7.8 | 1.8 | -12.7 | 6.6 |
|
BSE FMCG
| -6.7 | 10.0 | 0.5 | -8.4 | 3.3 | 8.3 | 9.1 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Nath Bio-Genes
| -17.7 | -12.1 | 28.4 | -38.9 | -3.0 | -25.7 | -18.4 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE FMCG
| -2.1 | 1.5 | 27.3 | 16.6 | 9.3 | 10.5 | -3.6 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Nath Bio-Genes
|
172.0 | 328.8 | 445.5 | 43.1 | 9.9 | 5.9 | 7.6 | 0.5 |
| 282.6 | 1,408.7 | 1,378.9 | 101.1 | 9.9 | 13.5 | 13.9 | 2.0 | |
| 164.4 | 3,398.2 | 1,463.4 | 73.6 | 6.1 | 16.3 | 46.3 | 6.5 | |
| 243.4 | 304.9 | 493.3 | 4.4 | 0.5 | 2.7 | 73.6 | 1.8 | |
| 101.8 | 203.0 | 117.8 | 14.8 | 14.6 | 18 | 13.7 | 2.3 | |
| 934.2 | 4,800.3 | 1,377.9 | 300.8 | 20.1 | 18.3 | 16 | 2.7 | |
| 425.0 | 14,747.8 | 10,267.2 | 636.9 | 9.0 | 16.2 | 22.7 | 3.4 | |
| 4.7 | 504.3 | 1,440.2 | 343.1 | 24.1 | 32.2 | 1.5 | 0.4 | |
| 261.8 | 290.5 | 14.1 | 1.1 | 7.5 | 18.1 | 274.6 | 42.1 | |
| 4.0 | 491.8 | 1,312.7 | 33.1 | 5.1 | 8.6 | 14.9 | 1.0 |
1 min read•By Research Desk
Nath Bio-Genes (India) Limited engages in the production, processing, and marketing of hybrid and GM seeds in India and internationally. It operates in two segments, Agricultural Activities and Trading Activities. The company offers fiber and oil... seeds, including cotton and mustard; seeds for field crops, such as bajra, corn, paddy, wheat, and jowar; fruit seeds; and seeds for vegetables comprising cabbage, chilli, onion, okra, tomato, brinjal, bottle gourd, bitter gourd, sponge gourd, ridge gourd, cucumber, coriander, sweet pepper, green peas, pumpkin, tinda, and French beans. It also provides crop protection supplements under the WINPro GOLii, WINall, and Win-Chi-Win names; and forage seeds under the NUTRIMAX GOLD and NUTRIMAX names. The company was founded in 1979 and is based in Mumbai, India. Read more
Incorporated
2000
Chairman
--
Managing Director
Satish Kagliwal
Headquarters
Chhatrapati Sambhajinagar - (Aurangabad), Maharashtra
Website
Our rating system has guided millions of investors in the past 20 years.
Annual Reports
Announcements
View Announcements
The share price of Nath Bio-Genes (India) Ltd is ₹172.00 (NSE) and ₹171.20 (BSE) as of 28-Apr-2026 IST. Nath Bio-Genes (India) Ltd has given a return of 1.77% in the last 3 years.
The P/E ratio of Nath Bio-Genes (India) Ltd is 7.62 times as on 28-Apr-2026, a 52 discount to its peers’ median range of 15.87 times.
The P/B ratio of Nath Bio-Genes (India) Ltd is 0.48 times as on 28-Apr-2026, a 75 discount to its peers’ median range of 1.95 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
7.18
|
0.43
|
|
2024
|
8.33
|
0.54
|
|
2023
|
7.69
|
0.47
|
|
2022
|
0.00
|
0.75
|
|
2021
|
10.24
|
0.93
|
The 52-week high and low of Nath Bio-Genes (India) Ltd are Rs 238.69 and Rs 126.15 as of 28-Apr-2026.
Nath Bio-Genes (India) Ltd has a market capitalisation of ₹ 329 Cr as on 28-Apr-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Nath Bio-Genes (India) Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.